Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.1
The freedom of self-administration
- Aspaveli is the first subcutaneous treatment for PNH that can be self-administered to suit patients’ lifestyles1
- Aspaveli provides the flexibility to self-infuse, at home or other locations, to suit patients’ lifestyles1
- Aspaveli is administered twice weekly as a 1080 mg subcutaneous infusion1
- Aspaveli can be self-administered using a commercially available infusion pump that can deliver doses up to 20 mL1
For full preparation and administration information, refer to the Aspaveli Summary of Product Characteristics and the infusion pump manufacturer’s instructions.
Learn more about how to administer Aspaveli
PP-20361